Takeda Pharmaceutical Q3 Earnings Call Highlights

Core Insights - Takeda Pharmaceutical revised its full-year revenue guidance downward to JPY 4.53 trillion, reflecting a low single-digit decline at constant exchange rates due to stronger-than-anticipated erosion of Vyvanse generics in the U.S. [1][7] - The company maintained its full-year guidance for core operating profit at JPY 1.15 trillion and core EPS at JPY 486, supported by disciplined cost management [1][7] - Takeda reported adjusted free cash flow of JPY 625.9 billion for the period, indicating strong cash generation despite a $1.2 billion upfront payment to Innovent Biologics [2][7] Financial Performance - For the nine-month period, Takeda's revenue was just over JPY 3.4 trillion, down 3.3% year over year (down 2.8% at constant exchange rates) [3] - Core operating profit decreased by 3.4% year over year to JPY 971.6 billion, while reported operating profit rose by 1.2% to JPY 422.4 billion [3] - Core EPS was reported at JPY 428, with reported EPS at JPY 137 [3] Growth Drivers - Growth-and-launch products accounted for over 50% of total revenue, growing 6.7% year to date, driven by Entyvio and vaccines [5][8] - Entyvio experienced a growth of 7.4% at constant exchange rates, attributed to strong third-quarter performance and formulary wins [9] - Qdenga vaccine growth accelerated to 22.1%, primarily driven by demand in Brazil [10] Pipeline Developments - Takeda is preparing for several late-stage product launches, with three key pipeline assets—oveporexton, rusfertide, and zasocitinib—expected to shape future growth [4][11] - Positive phase III readouts for oveporexton and rusfertide have led to NDA filings, with launches planned within the current calendar year [6][11] - Zasocitinib showed significant efficacy in psoriasis treatment, with a summer submission target and a potential launch in 2027 [14] Leadership Transition - CEO Christophe Weber announced his transition from the main presenter role, with Julie Kim set to take over leadership in June [17]